ScPharmaceuticals Analyst Ratings
ScPharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/07/2023 | 185.71% | Craig-Hallum | → $20 | Initiates Coverage On | → Buy |
| 08/11/2023 | 157.14% | HC Wainwright & Co. | → $18 | Reiterates | Buy → Buy |
| 08/02/2023 | 157.14% | HC Wainwright & Co. | → $18 | Reiterates | Buy → Buy |
| 07/19/2023 | 157.14% | HC Wainwright & Co. | → $18 | Reiterates | Buy → Buy |
| 06/08/2023 | 157.14% | HC Wainwright & Co. | → $18 | Reiterates | Buy → Buy |
| 05/11/2023 | 185.71% | Maxim Group | $13 → $20 | Maintains | Buy |
| 05/11/2023 | 157.14% | HC Wainwright & Co. | → $18 | Reiterates | Buy → Buy |
| 03/23/2023 | 157.14% | HC Wainwright & Co. | → $18 | Reiterates | → Buy |
| 01/27/2023 | 85.71% | SVB Leerink | $12 → $13 | Maintains | Outperform |
| 12/01/2022 | 257.14% | Cowen & Co. | → $25 | Initiates Coverage On | → Outperform |
| 11/10/2022 | 157.14% | HC Wainwright & Co. | $15 → $18 | Maintains | Buy |
| 11/10/2022 | 71.43% | SVB Leerink | $11 → $12 | Maintains | Outperform |
| 10/21/2022 | 100% | Jefferies | → $14 | Assumes | → Buy |
| 10/11/2022 | 57.14% | SVB Leerink | $6 → $11 | Upgrades | Market Perform → Outperform |
| 08/02/2022 | — | Maxim Group | Initiates Coverage On | → Buy | |
| 05/17/2022 | -14.29% | SVB Leerink | $5 → $6 | Maintains | Market Perform |
| 09/09/2021 | -14.29% | SVB Leerink | → $6 | Initiates Coverage On | → Market Perform |
| 11/30/2020 | 71.43% | SVB Leerink | $11 → $12 | Maintains | Market Perform |
| 05/27/2020 | 42.86% | SVB Leerink | $12 → $10 | Maintains | Market Perform |
| 05/13/2020 | 114.29% | HC Wainwright & Co. | $13 → $15 | Reiterates | → Buy |
| 10/15/2019 | 85.71% | HC Wainwright & Co. | → $13 | Initiates Coverage On | → Buy |
| 01/30/2019 | -28.57% | Leerink Swann | $12 → $5 | Downgrades | Outperform → Market Perform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 09/07/2023 | 185.71% | 克雷格-哈勒姆 | →$20 | 开始承保 | →购买 |
| 2023年08月11日 | 157.14% | HC Wainwright公司 | →$18 | 重申 | 购买→购买 |
| 08/02/2023 | 157.14% | HC Wainwright公司 | →$18 | 重申 | 购买→购买 |
| 07/19/2023 | 157.14% | HC Wainwright公司 | →$18 | 重申 | 购买→购买 |
| 06/08/2023 | 157.14% | HC Wainwright公司 | →$18 | 重申 | 购买→购买 |
| 2023年05月11日 | 185.71% | Maxim集团 | $13→$20 | 维护 | 买 |
| 2023年05月11日 | 157.14% | HC Wainwright公司 | →$18 | 重申 | 购买→购买 |
| 03/23/2023 | 157.14% | HC Wainwright公司 | →$18 | 重申 | →购买 |
| 2023年1月27日 | 85.71% | SVB Leerink | $12→$13 | 维护 | 跑赢大盘 |
| 12/01/2022 | 257.14% | 考恩公司 | →$25 | 开始承保 | →跑赢大盘 |
| 2022年11月10日 | 157.14% | HC Wainwright公司 | $15→$18 | 维护 | 买 |
| 2022年11月10日 | 71.43% | SVB Leerink | $11→$12 | 维护 | 跑赢大盘 |
| 2022年10月21日 | 100% | 杰富瑞 | →$14 | 假设 | →购买 |
| 2022年10月11日 | 57.14% | SVB Leerink | $6→$11 | 升级 | 市场表现优于→ |
| 08/02/2022 | - | Maxim集团 | 开始承保 | →购买 | |
| 2022/05/17 | -14.29% | SVB Leerink | $5→$6 | 维护 | 市场表现 |
| 09/09/2021 | -14.29% | SVB Leerink | →$6 | 开始承保 | →市场表现 |
| 11/30/2020 | 71.43% | SVB Leerink | $11→$12 | 维护 | 市场表现 |
| 05/27/2020 | 42.86% | SVB Leerink | $12→$10 | 维护 | 市场表现 |
| 2020/05/13 | 114.29% | HC Wainwright公司 | $13→$15 | 重申 | →购买 |
| 2019年10月15日 | 85.71% | HC Wainwright公司 | →$13 | 开始承保 | →购买 |
| 2019年01月30日 | -28.57% | 利林克·斯旺 | $12→$5 | 评级下调 | 跑赢→市场表现 |
What is the target price for scPharmaceuticals (SCPH)?
ScPharmPharmticals(SCPH)的目标价是多少？
The latest price target for scPharmaceuticals (NASDAQ: SCPH) was reported by Craig-Hallum on September 7, 2023. The analyst firm set a price target for $20.00 expecting SCPH to rise to within 12 months (a possible 185.71% upside). 14 analyst firms have reported ratings in the last year.
克雷格-哈勒姆于2023年9月7日报道了SCPharmticals(纳斯达克代码：SCPH)的最新目标价。这家分析公司将目标价定为20美元，预计SCPH将在12个月内上涨(可能上涨185.71%)。过去一年，有14家分析公司公布了评级。
What is the most recent analyst rating for scPharmaceuticals (SCPH)?
ScPharmticals(SCPH)的最新分析师评级是多少？
The latest analyst rating for scPharmaceuticals (NASDAQ: SCPH) was provided by Craig-Hallum, and scPharmaceuticals initiated their buy rating.
纳斯达克(Sequoia Capital：SCPH)的最新分析师评级由克雷格-哈勒姆提供，SCPharmPharmticals启动了买入评级。
When is the next analyst rating going to be posted or updated for scPharmaceuticals (SCPH)?
ScPharmticals(SCPH)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of scPharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for scPharmaceuticals was filed on September 7, 2023 so you should expect the next rating to be made available sometime around September 7, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与scPharmPharmticals的高管和客户交谈，以及收听收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。ScPharmticals的上一次评级是在2023年9月7日提交的，所以你应该预计下一次评级将在2024年9月7日左右的某个时候公布。
Is the Analyst Rating scPharmaceuticals (SCPH) correct?
分析师对SCPharmPharmticals(SCPH)的评级正确吗？
While ratings are subjective and will change, the latest scPharmaceuticals (SCPH) rating was a initiated with a price target of $0.00 to $20.00. The current price scPharmaceuticals (SCPH) is trading at is $7.00, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的scPharmPharmticals(SCPH)评级是以0.00美元至20.00美元的目标价启动的。ScPharmticals(SCPH)目前的交易价格为7.00美元，在分析师的预测范围内。